MedPath

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
Registration Number
NCT00017550
Lead Sponsor
Genzyme, a Sanofi Company
Brief Summary

RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome.

PURPOSE: Randomized phase II trial to compare the effectiveness of antithymocyte globulin with that of supportive care in treating patients who have myelodysplastic syndrome.

Detailed Description

OBJECTIVES:

* Compare the clinical response rate of patients with early myelodysplastic syndrome treated with rabbit anti-thymocyte globulin vs standard supportive care.

* Evaluate the safety of anti-thymocyte globulin in these patients.

* Compare the time to and duration of clinical response, rates of partial response and therapy failure, and rate of disease progression in patients treated with these regimens.

* Compare the ECOG performance score, number of transfusions and/or growth factor use, and maximum time between transfusions in patients treated with these regimens.

* Compare the infection risk, use of medical resources, and quality of clinical response in patients treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to myelodysplastic syndrome (MDS) subtype (refractory anemia (RA) vs RA with excess blasts or hypocellular MDS). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive rabbit anti-thymocyte globulin (ATG) IV over at least 8-12 hours on days 1-4.

* Arm II: Patients receive standard supportive therapy for 6 months. At the end of 6 months, patients may receive ATG as in arm I.

Patients are followed for 6 months.

PROJECTED ACCRUAL: A total of 72 patients (48 in arm I and 24 in arm II) will be accrued within a minimum of 6 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (28)

Hackensack University Medical Center

πŸ‡ΊπŸ‡Έ

Hackensack, New Jersey, United States

Department of Medicine

πŸ‡¨πŸ‡¦

Vancouver, British Columbia, Canada

Sylvester Cancer Center, University of Miami

πŸ‡ΊπŸ‡Έ

Miami, Florida, United States

Holden Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Iowa City, Iowa, United States

Siteman Cancer Center

πŸ‡ΊπŸ‡Έ

Saint Louis, Missouri, United States

Indiana Blood and Marrow Transplant

πŸ‡ΊπŸ‡Έ

Beech Grove, Indiana, United States

Winship Cancer Institute of Emory University

πŸ‡ΊπŸ‡Έ

Atlanta, Georgia, United States

Princess Margaret Hospital

πŸ‡¨πŸ‡¦

Toronto, Ontario, Canada

New York Presbyterian Hospital - Cornell Campus

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Mount Sinai Medical Center, NY

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Cleveland Clinic Taussig Cancer Center

πŸ‡ΊπŸ‡Έ

Cleveland, Ohio, United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

πŸ‡ΊπŸ‡Έ

Baltimore, Maryland, United States

Rush Cancer Institute

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

University of Missouri Kansas City School of Medicine

πŸ‡ΊπŸ‡Έ

Kansas City, Missouri, United States

Medical College of Wisconsin

πŸ‡ΊπŸ‡Έ

Milwaukee, Wisconsin, United States

University of Florida Health Science Center

πŸ‡ΊπŸ‡Έ

Gainesville, Florida, United States

Washington Cancer Institute

πŸ‡ΊπŸ‡Έ

Washington, District of Columbia, United States

Tulane University School of Medicine

πŸ‡ΊπŸ‡Έ

New Orleans, Louisiana, United States

Saint Louis University Cancer Center

πŸ‡ΊπŸ‡Έ

Saint Louis, Missouri, United States

Foothills Hospital

πŸ‡¨πŸ‡¦

Calgary, Alberta, Canada

Texas Oncology P.A.

πŸ‡ΊπŸ‡Έ

Dallas, Texas, United States

Comprehensive Cancer Center at Wake Forest University

πŸ‡ΊπŸ‡Έ

Winston-Salem, North Carolina, United States

New York Medical College

πŸ‡ΊπŸ‡Έ

Valhalla, New York, United States

James P. Wilmot Cancer Center

πŸ‡ΊπŸ‡Έ

Rochester, New York, United States

Veterans Affairs Medical Center - Tampa (Haley)

πŸ‡ΊπŸ‡Έ

Tampa, Florida, United States

H. Lee Moffitt Cancer Center and Research Institute

πŸ‡ΊπŸ‡Έ

Tampa, Florida, United States

University of Nebraska Medical Center

πŸ‡ΊπŸ‡Έ

Omaha, Nebraska, United States

University of Kansas Medical Center

πŸ‡ΊπŸ‡Έ

Kansas City, Kansas, United States

Β© Copyright 2025. All Rights Reserved by MedPath